Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Candel Therapeutics (CADL) Return on Capital Employed (2021 - 2023)

Historic Return on Capital Employed for Candel Therapeutics (CADL) over the last 3 years, with Q3 2023 value amounting to 0.82%.

  • Candel Therapeutics' Return on Capital Employed fell 4100.0% to 0.82% in Q3 2023 from the same period last year, while for Sep 2023 it was 0.82%, marking a year-over-year decrease of 4100.0%. This contributed to the annual value of 0.45% for FY2022, which is 100.0% down from last year.
  • As of Q3 2023, Candel Therapeutics' Return on Capital Employed stood at 0.82%, which was down 4100.0% from 0.66% recorded in Q2 2023.
  • In the past 5 years, Candel Therapeutics' Return on Capital Employed ranged from a high of 0.29% in Q4 2021 and a low of 0.82% during Q3 2023
  • In the last 3 years, Candel Therapeutics' Return on Capital Employed had a median value of 0.41% in 2022 and averaged 0.48%.
  • In the last 5 years, Candel Therapeutics' Return on Capital Employed changed by 0bps in 2022 and then tumbled by -4100bps in 2023.
  • Candel Therapeutics' Return on Capital Employed (Quarter) stood at 0.29% in 2021, then crashed by -55bps to 0.46% in 2022, then tumbled by -79bps to 0.82% in 2023.
  • Its Return on Capital Employed stands at 0.82% for Q3 2023, versus 0.66% for Q2 2023 and 0.53% for Q1 2023.